# US 11,306,311 B2 · Long non-coding RNA in cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,306,311 B2
- Document ID: US11306311B2
- Status: Granted
- Kind: B2
- Application number: 16/620,700
- Filed: 2018-06-08
- Published: 2020-05-07
- Granted: 2022-04-19
- Earliest claimed: 2017-06-08
- Applicants: Chandrasekhar Kanduri; Mohamad Moustafa Mahmoud Ali; Luisa Statello; Vijay Suresh Akhade; Santhilal Subhash; Subazini Thankaswamy Kosalai
- Inventors: Chandrasekhar Kanduri; Mohamad Moustafa Mahmoud Ali; Luisa Statello; Vijay Suresh Akhade; Santhilal Subhash; Subazini Thankaswamy Kosalai
- Web page: https://patentgrep.com/patent/US11306311B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 35/00: Antineoplastic agents
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12Q 1/68: involving nucleic acids
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 2310/11: Antisense
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

There are provided polynucleotides that is able to bind to and inhibit the long non coding RNA transcript SCAT7. These polynucleotides can be used for the treatment of cancer. Expression analysis of SCAT7 can be used for diagnosis of cancer.

## Claims

### Claim 1

A method for treatment of a cancer which is resistant to chemotherapy comprising administering to a patient who has the cancer which is resistant to chemotherapy a polynucleotide that is able to bind to and inhibit a long non-coding RNA transcript that comprises or consists of the sequence SEQ ID NO 1 or SEQ ID NO 2 or a sequence that has at least 95% sequence identity to SEQ ID NO 1 or SEQ ID NO 2.

### Claim 2 (depends on 1)

The method of treatment of claim 1, wherein the disease is selected from lung cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, prostate cancer and endometrial cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the polynucleotide comprises or consists of a sequence selected from the group consisting of SEQ ID NO 4 to SEQ ID NO 13.

### Claim 4 (depends on 1)

The method of claim 1, wherein the polynucleotide is a DNA antisense polynucleotide selected from SEQ ID NO 4 and SEQ ID NO 5, a shRNA polynucleotide selected from SEQ ID NO 6 and SEQ ID NO 7, or a siRNA polynucleotide which is a duplex of SEQ ID NO 8 and SEQ ID NO 9, a duplex of SEQ ID NO 10 and SEQ ID NO 11 or a duplex of SEQ ID NO 12 and SEQ ID NO 13.

### Claim 5 (depends on 1)

The method of claim 1 where the cancer is resistant to an agent selected from the group consisting of actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bleomycin, bortezomib, capecitabine, cisplatin, carboplatin, chlorambucil cyclophosphamide, cytarabine, daunorubicin, dicycloplatin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, lipoplatin, mechlorethamine, mercaptopurine, methotrexate, mitoxantrone, nedaplatin, oxaliplatin, paclitaxel, pemetrexed, picoplatin, satraplatin, teniposide, tioguanine, topotecan, valrubicin, vemurafenib, vinblastine, vincristine, vindesine and vinorelbine.

### Claim 6 (depends on 1)

The method of claim 1 where the cancer is resistant to a platinum-based or platinum-containing chemotherapeutic agent.

### Claim 7 (depends on 1)

The method of claim 1 where the cancer is resistant to an agent selected from the group consisting of: cisplatin, carboplatin, dicycloplatin, lipoplatin, nedaplatin, oxaliplatin, picoplatin, and satraplatin.

### Claim 8 (depends on 1)

The method of claim 1 where the cancer is resistant to cisplatin.